Intensive lipid-lowering therapy with 80 mg of atorvastatin per day in patients with stable CHD provides significant clinical benefit beyond that afforded by treatment with 10 mg of atorvastatin per day

La terapia intensiva de reducción del colesterol con atorvastatin de 80 mg al día en pacientes con enfermedad cardíaca coronaria proporciona un beneficio clínico significativamente superior al conseguido con el tratamiento con 10 mg al día de atorvastatin

«Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease»

Estudio Treating to New Targets (TNT). 10,001 participantes. Dos dosis diferentes de una estatina. A mayor dosis, más se reduce el colesterol LDL.

Datos de mortalidad por cualquier causa:

Más muertes en el grupo con mayor dosis: 5.7% frente a un 5.6%. Beneficio clínico significativo…

Conflictos de interés

Copio textualmente del artículo.

Funded by Pfizer

Dr. LaRosa reports having received consulting fees from Pfizer, Merck, Bristol-Myers Squibb, and AstraZeneca and lecture fees from Pfizer; Dr. Grundy lecture fees from Merck, Pfizer, Kos Pharmaceutical, Abbott, and AstraZeneca and grant support from Kos Pharmaceutical and Merck; and Dr. Waters consulting fees from AstraZeneca and Pfizer; lecture fees from Merck, Pfizer, and Novartis; and grant support from Merck and Johnson & Johnson. Dr. Shear is an employee of Pfizer and owns stock in that company. Dr. Barter reports having received consulting fees from Pfizer, AstraZeneca, and Sanofi-Aventis; lecture fees from Pfizer, AstraZeneca, FournierPharma, and Sanofi-Aventis; and grant support from Pfizer; and Dr. Fruchart consulting fees from Pfizer and Fournier and lecture fees from Merck, Fournier, Pierre Fabrie, and AstraZeneca. Dr. Gotto reports having received consulting fees from AstraZeneca, Bristol-Myers Squibb, Merck, ScheringPlough, Pfizer, Novartis, and Reliant and lecture fees from AstraZeneca, Merck, ScheringPlough, Pfizer, and Reliant and having testified before the Food and Drug Administration on behalf of Johnson & Johnson–Merck. Dr. Greten reports having received consulting and lecture fees from Pfizer, Merck, and ScheringPlough; Dr. Kastelein consulting fees, lecture fees, and grant support from Pfizer, Merck, ScheringPlough, AstraZeneca, Bristol-Myers Squibb, and Sankyo; Dr. Shepherd consulting fees from AstraZeneca, GlaxoSmithKline, Merck, ScheringPlough and Oxford Biosensors and lecture fees from AstraZeneca, Merck, and ScheringPlough; and Dr. Wenger consulting fees from Eli Lilly, Merck, Bristol-Myers Squibb, Pfizer, and Kos Pharmaceuticals; lecture fees from Eli Lilly, Pfizer, Novartis, Merck, Bristol-Myers Squibb, and Kos Pharmaceuticals; and grant support from Eli Lilly, Novartis, Bristol-Myers Squibb, and AstraZeneca. We are indebted to all the trial participants; to the large number of doctors, nurses, and hospital administrative staff in various countries for their long-term commitment to the study; and to Diane Hessinger, Roger Chan, Andrei Breazna, Eric Gibson, Liz Cusenza, Sheila Auster, Patrick Ferrebee, and Roddy Carter (all full-time employees of Pfizer) for their contributions.

Leer más:

• ¿Cómo reaccionas tú cuando alguien te engaña? ASPEN
• ¿Cómo reaccionas tú cuando alguien te engaña? SEARCH
• ¿Cómo reaccionas tú cuando alguien te engaña? ALLHAT-LLT
• ¿Cómo reaccionas tú cuando alguien te engaña? JUPITER
• ¿Cómo reaccionas tú cuando alguien te engaña? SHARP
• ¿Cómo reaccionas tú cuando alguien te engaña? PROSPER
• ¿Cómo reaccionas tú cuando alguien te engaña? IMPROVE IT
• ¿Qué les pasó a las estatinas en el 2004?
• ¿Vas a saber tú más que el médico?